Clara Lundetoft Clausen
Research Subjects
Clara Lundetoft Clausen has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Thomas Benfield
Department of Infectious Diseases Copenhagen University Hospital—Amager and Hvidovre Hvidovre Denmark
7 shared publicationsDaniel Faurholt-Jepsen
Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark
3 shared publicationsNiels Erik Skakkebæk
Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
3 shared publicationsOle Snorgaard
Department of Endocrinology Copenhagen University Hospital—Amager and Hvidovre Copenhagen Denmark
3 shared publicationsRikke Krogh-Madsen
Center of Clinical Research and Disruption of Infectious Diseases (CREDID), Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark
3 shared publications- Thomas Benfield
Department of Infectious Diseases Copenhagen University Hospital‐Amager and Hvidovre Hvidovre Denmark
3 shared publications
Latest Publications
- Open Access
Antibiotic Exposure and Risk of Acute Kidney Injury in Individuals With Staphylococcus aureus Bacteremia
Staphylococcus aureus bacteremia (SAB) is associated with acute kidney injury (AKI). Recent reports have suggested that isoxazolyl penicillins are associated with AKI. To further investigate the relationship between antibiotic treatment and risk of AKI in patients with SAB, we studied a cohort of adults with methicillin‐susceptible SAB. AKI was defined using modified KDIGO criteria. Time‐dependent associations between antibiotic exposure and AKI were evaluated using landmark analyses combined with Fine–Gray competing risk models, treating death and hospital discharge as competing events. Absolute risks were estimated using the parametric g‐formula. Of the 1867 cases, 466 (25.0%) developed AKI within 14 days of blood culture. Accounting for time‐varying antibiotic exposure and competing risks, dicloxacillin, but not penicillin and cefuroxime, was associated with an increased rate of AKI at later landmarks within Days 1–5, with a higher rate observed on Day 5 (sHR: 4.84, 95% CI: 1.58–14.79). Absolute risk estimates were similar early after infection but diverged at later time points. In patients with SAB, AKI was common and occurred predominantly within the first 5 days. When accounting for time‐varying antibiotic exposure and competing risks, dicloxacillin was associated with an increased rate of AKI at later landmarks.
Open AccessAntibiotic Exposure and Risk of Acute Kidney Injury in Individuals With Staphylococcus aureus Bacteremia
Staphylococcus aureus bacteremia (SAB) is associated with acute kidney injury (AKI). Recent reports have suggested that isoxazolyl penicillins are associated with AKI. To further investigate the relationship between antibiotic treatment and risk of AKI in patients with SAB, we studied a cohort of adults with methicillin‐susceptible SAB. AKI was defined using modified KDIGO criteria. Time‐dependent associations between antibiotic exposure and AKI were evaluated using landmark analyses combined with Fine–Gray competing risk models, treating death and hospital discharge as competing events. Absolute risks were estimated using the parametric g‐formula. Of the 1867 cases, 466 (25.0%) developed AKI within 14 days of blood culture. Accounting for time‐varying antibiotic exposure and competing risks, dicloxacillin, but not penicillin and cefuroxime, was associated with an increased rate of AKI at later landmarks within Days 1–5, with a higher rate observed on Day 5 (sHR: 4.84, 95% CI: 1.58–14.79). Absolute risk estimates were similar early after infection but diverged at later time points. In patients with SAB, AKI was common and occurred predominantly within the first 5 days. When accounting for time‐varying antibiotic exposure and competing risks, dicloxacillin was associated with an increased rate of AKI at later landmarks.
Glycemic Variability and Diabetic Events in Hospitalized Patients With COVID‐19 Treated With Dexamethasone: An Observational Cohort Study
Although dexamethasone reduces mortality in patients with COVID‐19, plasma glucose (PG) levels increase upon initiation. In a multicenter observational cohort of 530 adults, we estimated glycemic variability based on baseline HbA1c among patients with normoglycemia ( N = 238), prediabetes ( N = 159), unknown ( N = 63), and known diabetes ( N = 159). Glycemic variability, diabetic‐ and hyperglycemic events (≥ 11.1 and ≥ 16 mmol/L) were analyzed using a linear mixed model and competing risks analysis adjusted for confounders. Before dexamethasone, mean PG levels were similar in those with normoglycemia (6.5 mmol/L) and prediabetes (6.6 mmol/L), but higher in unknown (8.5 mmol/L) and known diabetes (9.9 mmol/L). After treatment, PG increased across all groups. Prediabetes showed a larger increase (1.5 mmol/L) than normoglycemia (0.7 mmol/L, p = 0.002), and known diabetes had the highest increase (2.4 mmol/L, p < 0.001), reaching an average of 12.6 mmol/L. All groups except prediabetes returned to baseline after dexamethasone. The cumulative incidence of diabetic events was 98% in known diabetes, 67% in unknown diabetes, 31% in prediabetes, and 8% in normoglycemia, with significant differences between groups ( p < 0.001). We conclude that dexamethasone treatment increased average PG and caused frequent hyperglycemic events in patients with prediabetes, unknown, and known diabetes, while persistent PG elevation post‐treatment occurred in prediabetes.
Glycemic Variability and Diabetic Events in Hospitalized Patients With COVID‐19 Treated With Dexamethasone: An Observational Cohort Study
Although dexamethasone reduces mortality in patients with COVID‐19, plasma glucose (PG) levels increase upon initiation. In a multicenter observational cohort of 530 adults, we estimated glycemic variability based on baseline HbA1c among patients with normoglycemia ( N = 238), prediabetes ( N = 159), unknown ( N = 63), and known diabetes ( N = 159). Glycemic variability, diabetic‐ and hyperglycemic events (≥ 11.1 and ≥ 16 mmol/L) were analyzed using a linear mixed model and competing risks analysis adjusted for confounders. Before dexamethasone, mean PG levels were similar in those with normoglycemia (6.5 mmol/L) and prediabetes (6.6 mmol/L), but higher in unknown (8.5 mmol/L) and known diabetes (9.9 mmol/L). After treatment, PG increased across all groups. Prediabetes showed a larger increase (1.5 mmol/L) than normoglycemia (0.7 mmol/L, p = 0.002), and known diabetes had the highest increase (2.4 mmol/L, p < 0.001), reaching an average of 12.6 mmol/L. All groups except prediabetes returned to baseline after dexamethasone. The cumulative incidence of diabetic events was 98% in known diabetes, 67% in unknown diabetes, 31% in prediabetes, and 8% in normoglycemia, with significant differences between groups ( p < 0.001). We conclude that dexamethasone treatment increased average PG and caused frequent hyperglycemic events in patients with prediabetes, unknown, and known diabetes, while persistent PG elevation post‐treatment occurred in prediabetes.
- Open Access
- 18 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1) , ofaf778
Outcomes Related to Bacterial Co-Infection and Antibiotic Use in Adults Hospitalized With Respiratory Syncytial Virus Compared with Influenza
Background: Adults hospitalized with respiratory syncytial virus (RSV) face mortality risks comparable to or higher than those with influenza A or B. However, studies on the impact of bacterial co-infections on mortality are inconsistent. Methods: This multicenter cohort study included adults hospitalized with RSV, influenza A, or B over 3 years at two tertiary care hospitals. Microbiological testing, bacterial co-infections, antibiotic use, and their association with clinical outcomes were analyzed using adjusted linear and logistic regression models. Results: Of 986 patients, 352 (36%) had RSV, 347 (35%) influenza A, and 287 (29%) influenza B. The median age was 74 years, 54% were women, and 76% had at least one comorbidity. Overall, 32% had pneumonia. The prevalence of bacterial co-infections was comparable across patients with RSV (23%), influenza A (25%), and B (28%). Among patients without bacterial co-infection, antibiotic use within 48 hours remained common across all virus groups (77%, 71%, and 75%, respectively). In adjusted analyses, bacterial co-infection in patients with RSV was not associated with mortality at 14, 30, or 90 days, high-flow oxygen therapy, mechanical ventilation, or length of stay (LOS). Early antibiotic treatment was associated with prolonged LOS but not improved survival. Conclusions: Bacterial co-infections were identified in approximately one-quarter of patients with RSV, influenza A, and B. Among patients with RSV, bacterial co-infection was not associated with adverse clinical outcomes, and early antibiotic treatment did not appear to improve clinical outcomes.
- 18 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1) , ofaf778
Open AccessOutcomes Related to Bacterial Co-Infection and Antibiotic Use in Adults Hospitalized With Respiratory Syncytial Virus Compared with Influenza
Background: Adults hospitalized with respiratory syncytial virus (RSV) face mortality risks comparable to or higher than those with influenza A or B. However, studies on the impact of bacterial co-infections on mortality are inconsistent. Methods: This multicenter cohort study included adults hospitalized with RSV, influenza A, or B over 3 years at two tertiary care hospitals. Microbiological testing, bacterial co-infections, antibiotic use, and their association with clinical outcomes were analyzed using adjusted linear and logistic regression models. Results: Of 986 patients, 352 (36%) had RSV, 347 (35%) influenza A, and 287 (29%) influenza B. The median age was 74 years, 54% were women, and 76% had at least one comorbidity. Overall, 32% had pneumonia. The prevalence of bacterial co-infections was comparable across patients with RSV (23%), influenza A (25%), and B (28%). Among patients without bacterial co-infection, antibiotic use within 48 hours remained common across all virus groups (77%, 71%, and 75%, respectively). In adjusted analyses, bacterial co-infection in patients with RSV was not associated with mortality at 14, 30, or 90 days, high-flow oxygen therapy, mechanical ventilation, or length of stay (LOS). Early antibiotic treatment was associated with prolonged LOS but not improved survival. Conclusions: Bacterial co-infections were identified in approximately one-quarter of patients with RSV, influenza A, and B. Among patients with RSV, bacterial co-infection was not associated with adverse clinical outcomes, and early antibiotic treatment did not appear to improve clinical outcomes.
- Open Access
- 15 July 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 98-10
Hyperglycemia and insulin use in patients with COVID-19 and severe hypoxemia allocated to 12 mg vs. 6 mg of dexamethasone: a secondary analysis of the COVID STEROID 2 randomized trial
- 15 July 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 98-10
Open AccessHyperglycemia and insulin use in patients with COVID-19 and severe hypoxemia allocated to 12 mg vs. 6 mg of dexamethasone: a secondary analysis of the COVID STEROID 2 randomized trial
- Open Access
- 20 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae513
Clinical Manifestations and Outcomes in Adults Hospitalized With Respiratory Syncytial Virus and Influenza a/B: A Multicenter Observational Cohort Study
Respiratory syncytial virus (RSV) and influenza cause significant health challenges, particularly for individuals with comorbid conditions and older adults. However, information on the clinical manifestations and outcomes of adults hospitalized with RSV in Europe remains limited. This multicenter observational cohort study of adults hospitalized with RSV or influenza A or B from March 2016 to April 2020 investigated the clinical manifestations, mortality risk factors, and association with 90-day mortality rates by logistic regression analysis after adjustment for covariates. Of 988 patients hospitalized with either virus, 353 had RSV, 347 had influenza A, and 288 had influenza B infection. Patients with RSV, compared with those with influenza A or B, were more likely to have comorbid conditions (83% for RSV vs 72% for influenza A [P = .03] and 74% for influenza B [P = .001]) or pneumonia (41% vs 29% [P = .03] and 24% [P < .001], respectively). After adjustment for covariates, RSV infection was associated with an increased all-cause mortality rate within 90 days compared with influenza B (odds ratio, 2.16 [95% confidence interval, 1.20–3.87]; P = .01) but not influenza A (1.38 [.84–2.29]; P = .21). Increasing age and present pneumonia were identified as independent mortality risk factors in patients with RSV. Older adults hospitalized with RSV infections are at a higher risk of dying within 90 days of hospitalization than patients admitted with influenza B but at a similar risk as those admitted with influenza A, emphasizing the detrimental effects and severity of older patients being infected with RSV. Our findings underscore the need for strategic testing and vaccination approaches to mitigate the impact of RSV among older adults.
- 20 September 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (10) , ofae513
Open AccessClinical Manifestations and Outcomes in Adults Hospitalized With Respiratory Syncytial Virus and Influenza a/B: A Multicenter Observational Cohort Study
Respiratory syncytial virus (RSV) and influenza cause significant health challenges, particularly for individuals with comorbid conditions and older adults. However, information on the clinical manifestations and outcomes of adults hospitalized with RSV in Europe remains limited. This multicenter observational cohort study of adults hospitalized with RSV or influenza A or B from March 2016 to April 2020 investigated the clinical manifestations, mortality risk factors, and association with 90-day mortality rates by logistic regression analysis after adjustment for covariates. Of 988 patients hospitalized with either virus, 353 had RSV, 347 had influenza A, and 288 had influenza B infection. Patients with RSV, compared with those with influenza A or B, were more likely to have comorbid conditions (83% for RSV vs 72% for influenza A [P = .03] and 74% for influenza B [P = .001]) or pneumonia (41% vs 29% [P = .03] and 24% [P < .001], respectively). After adjustment for covariates, RSV infection was associated with an increased all-cause mortality rate within 90 days compared with influenza B (odds ratio, 2.16 [95% confidence interval, 1.20–3.87]; P = .01) but not influenza A (1.38 [.84–2.29]; P = .21). Increasing age and present pneumonia were identified as independent mortality risk factors in patients with RSV. Older adults hospitalized with RSV infections are at a higher risk of dying within 90 days of hospitalization than patients admitted with influenza B but at a similar risk as those admitted with influenza A, emphasizing the detrimental effects and severity of older patients being infected with RSV. Our findings underscore the need for strategic testing and vaccination approaches to mitigate the impact of RSV among older adults.
- Open Access
- 21 June 2024
- Published by Bioscientifica in Endocrine Connections
- Vol. 13 (8)
Endogenous serum glucocorticoid concentrations, steroidogenic enzyme activity, and 90-day mortality in patients hospitalized with COVID-19: an observational cohort study
In the context of severe coronavirus disease 2019 (COVID-19) illness, we examined endogenous glucocorticoid concentrations, steroidogenic enzyme activity, and their correlation with inflammation and patient outcomes. This observational study included 125 hospitalized COVID-19 patients and 101 healthy individuals as a reference group. We utilized LC-MS to assess serum concentrations of 11-deoxycortisol, cortisol, and cortisone, as well as activities of steroidogenic enzymes (11β-hydroxylase and 11β-hydroxysteroid-dehydrogenase type 1). Cox proportional hazards regression analysis and competing risk analysis were employed to analyze associations between glucocorticoid concentrations and outcomes, adjusting for relevant factors. In patients with COVID-19, cortisol concentrations were higher and cortisone concentrations were lower compared to the reference group, while 11-deoxycortisol concentrations were similar. Steroidogenic enzyme activity favored cortisol production. Correlations between glucocorticoid concentrations and inflammatory markers were low. A doubling in concentrations cortisol, was associated with increased 90-day mortality and mechanical ventilation (HR: 2.40 95% CI: (1.03–5.59) , P = 0.042 and HR: 3.83 (1.19–12.31), P = 0.024). A doubling in concentrations of 11-deoxycortisol was also associated to mortality (HR: 1.32 (1.05–1.67), P = 0.018), whereas concentrations of cortisone were associated with mechanical ventilation (HR: 5.09 (1.49–17.40), P = 0.009). In conclusion, serum concentrations of glucocorticoid metabolites were altered in patients hospitalized with severe COVID-19, and steroidogenic enzyme activity resulting in the conversion of cortisone to biologically active cortisol was preserved, thus not favoring critical-illness-related corticosteroid insufficiency at the enzymatic level. Glucocorticoid release did not counterbalance the hyperinflammatory state in patients with severe COVID-19. High serum concentrations of 11-deoxycortisol and cortisol were associated with 90-day mortality, and high serum concentrations of cortisol and cortisone were associated with mechanical ventilation.
- 21 June 2024
- Published by Bioscientifica in Endocrine Connections
- Vol. 13 (8)
Open AccessEndogenous serum glucocorticoid concentrations, steroidogenic enzyme activity, and 90-day mortality in patients hospitalized with COVID-19: an observational cohort study
In the context of severe coronavirus disease 2019 (COVID-19) illness, we examined endogenous glucocorticoid concentrations, steroidogenic enzyme activity, and their correlation with inflammation and patient outcomes. This observational study included 125 hospitalized COVID-19 patients and 101 healthy individuals as a reference group. We utilized LC-MS to assess serum concentrations of 11-deoxycortisol, cortisol, and cortisone, as well as activities of steroidogenic enzymes (11β-hydroxylase and 11β-hydroxysteroid-dehydrogenase type 1). Cox proportional hazards regression analysis and competing risk analysis were employed to analyze associations between glucocorticoid concentrations and outcomes, adjusting for relevant factors. In patients with COVID-19, cortisol concentrations were higher and cortisone concentrations were lower compared to the reference group, while 11-deoxycortisol concentrations were similar. Steroidogenic enzyme activity favored cortisol production. Correlations between glucocorticoid concentrations and inflammatory markers were low. A doubling in concentrations cortisol, was associated with increased 90-day mortality and mechanical ventilation (HR: 2.40 95% CI: (1.03–5.59) , P = 0.042 and HR: 3.83 (1.19–12.31), P = 0.024). A doubling in concentrations of 11-deoxycortisol was also associated to mortality (HR: 1.32 (1.05–1.67), P = 0.018), whereas concentrations of cortisone were associated with mechanical ventilation (HR: 5.09 (1.49–17.40), P = 0.009). In conclusion, serum concentrations of glucocorticoid metabolites were altered in patients hospitalized with severe COVID-19, and steroidogenic enzyme activity resulting in the conversion of cortisone to biologically active cortisol was preserved, thus not favoring critical-illness-related corticosteroid insufficiency at the enzymatic level. Glucocorticoid release did not counterbalance the hyperinflammatory state in patients with severe COVID-19. High serum concentrations of 11-deoxycortisol and cortisol were associated with 90-day mortality, and high serum concentrations of cortisol and cortisone were associated with mechanical ventilation.
- Open Access
- 1 January 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (1)
Pituitary–gonadal hormones associated with respiratory failure in men and women hospitalized with COVID-19: an observational cohort study
Aim: To explore pituitary-gonadal hormone concentrations and assess their association to inflammation, severe respiratory failure and mortality in hospitalized men and women with coronavirus disease 2019 (COVID-19) and compare these to hormone concentrations in hospitalized patients with bacterial community-acquired pneumonia (CAP), influenza virus CAP, and to concentrations in a reference group of healthy individuals. Methods: Serum concentrations of testosterone, estrone sulfate, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and interleukin-6 (IL-6) were measured within three days of admission. Associations were assessed by logistic regression analysis in patients with COVID-19, and results were reported as odds ratio with 95% confidence interval per two-fold reduction after adjustment for age, comorbidities, days to sample collection, and IL-6 concentrations. Results: In total 278 with COVID-19, 21 with influenza virus CAP, and 76 with bacterial CAP were included. Testosterone concentrations were suppressed in men hospitalized with COVID-19, bacterial- and influenza virus CAP and moderately suppressed in women. Reductions in testosterone (OR 3.43 [1.14-10.30], p=0.028) and LH (OR 2.51 [1.28-4.92], p=0.008) were associated higher odds of mechanical ventilation (MV) in men with COVID-19. In women with COVID-19, reductions in LH (OR 3.34 [1.02-10-90], p=0.046) and FSH (OR 2.52 [1.01-6.27], p=0.047) were associated with higher odds of MV. Conclusion: Low testosterone and LH concentrations were predictive of severe respiratory failure in men with COVID-19, whereas low concentrations of LH and FSH predicted severe respiratory failure in women with COVID-19.
- 1 January 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (1)
Open AccessPituitary–gonadal hormones associated with respiratory failure in men and women hospitalized with COVID-19: an observational cohort study
Aim: To explore pituitary-gonadal hormone concentrations and assess their association to inflammation, severe respiratory failure and mortality in hospitalized men and women with coronavirus disease 2019 (COVID-19) and compare these to hormone concentrations in hospitalized patients with bacterial community-acquired pneumonia (CAP), influenza virus CAP, and to concentrations in a reference group of healthy individuals. Methods: Serum concentrations of testosterone, estrone sulfate, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and interleukin-6 (IL-6) were measured within three days of admission. Associations were assessed by logistic regression analysis in patients with COVID-19, and results were reported as odds ratio with 95% confidence interval per two-fold reduction after adjustment for age, comorbidities, days to sample collection, and IL-6 concentrations. Results: In total 278 with COVID-19, 21 with influenza virus CAP, and 76 with bacterial CAP were included. Testosterone concentrations were suppressed in men hospitalized with COVID-19, bacterial- and influenza virus CAP and moderately suppressed in women. Reductions in testosterone (OR 3.43 [1.14-10.30], p=0.028) and LH (OR 2.51 [1.28-4.92], p=0.008) were associated higher odds of mechanical ventilation (MV) in men with COVID-19. In women with COVID-19, reductions in LH (OR 3.34 [1.02-10-90], p=0.046) and FSH (OR 2.52 [1.01-6.27], p=0.047) were associated with higher odds of MV. Conclusion: Low testosterone and LH concentrations were predictive of severe respiratory failure in men with COVID-19, whereas low concentrations of LH and FSH predicted severe respiratory failure in women with COVID-19.
- 25 April 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 187, 109880
Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort study
- 25 April 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 187, 109880
Glucometabolic changes influence hospitalization and outcome in patients with COVID-19: An observational cohort study
- Open Access
- 1 October 2021
- Published by Bioscientifica in Endocrine Connections
- Vol. 10 (10) , 1234-1242
Thyroid function in COVID-19 and the association with cytokine levels and mortality
The hypothalamic–pituitary–thyroid hormone axis might be affected in COVID-19, but existing studies have shown varying results. It has been hypothesized that hyperinflammation, as reflected by the secretion of cytokines, might induce thyroid dysfunction among patients with COVID-19. We explored thyroid hormone involvement in the acute phase of symptomatic COVID-19 and its possible associations with cytokine levels and mortality risk. This was a single-center study of 116 consecutive patients hospitalized for moderate-to-severe COVID-19 disease. Serum concentrations of thyroid-stimulating hormone (TSH), free thyroxine (T4), and 45 cytokines/chemokines were measured in all patients within 3 days of admission. Data were extracted retrospectively through a manual review of health records. At admission, 95 (81.9%) were euthyroid; while 21 (18.1%) had biochemically thyroid dysfunction including subclinical thyrotoxicosis (n = 11), overt thyrotoxicosis (n = 2), hypothyroidism (n = 1), non-thyroidal illness (n = 2), and normal TSH but high free T4 (n = 5). TSH levels were inversely correlated with IL-8 (rs = –0.248), IL-10 (rs = –0.253), IL-15 (rs = –0.213), IP-10 (rs = –0.334), and GM-CSF (rs = –0.254). Moreover, IL-8 levels, IP-10, and GM-CSF were significantly higher in patients with serum TSH < 0.4 mIU/L. Lastly, a two-fold increment of IL-8 and IL-10 was associated with significantly higher odds of having TSH < 0.4 mIU/L (odds ratio 1.86 (1.11–3.10) and 1.78 (1.03–3.06)). Serum TSH was not associated with 30- or 90-day mortality. In conclusion, this study suggests that fluctuations of TSH levels in patients with COVID-19 may be influenced by circulating IL-8, IL-10, IL-15, IP-10, and GM-CSF as previously described in autoimmune thyroid diseases.
- 1 October 2021
- Published by Bioscientifica in Endocrine Connections
- Vol. 10 (10) , 1234-1242
Open AccessThyroid function in COVID-19 and the association with cytokine levels and mortality
The hypothalamic–pituitary–thyroid hormone axis might be affected in COVID-19, but existing studies have shown varying results. It has been hypothesized that hyperinflammation, as reflected by the secretion of cytokines, might induce thyroid dysfunction among patients with COVID-19. We explored thyroid hormone involvement in the acute phase of symptomatic COVID-19 and its possible associations with cytokine levels and mortality risk. This was a single-center study of 116 consecutive patients hospitalized for moderate-to-severe COVID-19 disease. Serum concentrations of thyroid-stimulating hormone (TSH), free thyroxine (T4), and 45 cytokines/chemokines were measured in all patients within 3 days of admission. Data were extracted retrospectively through a manual review of health records. At admission, 95 (81.9%) were euthyroid; while 21 (18.1%) had biochemically thyroid dysfunction including subclinical thyrotoxicosis (n = 11), overt thyrotoxicosis (n = 2), hypothyroidism (n = 1), non-thyroidal illness (n = 2), and normal TSH but high free T4 (n = 5). TSH levels were inversely correlated with IL-8 (rs = –0.248), IL-10 (rs = –0.253), IL-15 (rs = –0.213), IP-10 (rs = –0.334), and GM-CSF (rs = –0.254). Moreover, IL-8 levels, IP-10, and GM-CSF were significantly higher in patients with serum TSH < 0.4 mIU/L. Lastly, a two-fold increment of IL-8 and IL-10 was associated with significantly higher odds of having TSH < 0.4 mIU/L (odds ratio 1.86 (1.11–3.10) and 1.78 (1.03–3.06)). Serum TSH was not associated with 30- or 90-day mortality. In conclusion, this study suggests that fluctuations of TSH levels in patients with COVID-19 may be influenced by circulating IL-8, IL-10, IL-15, IP-10, and GM-CSF as previously described in autoimmune thyroid diseases.
- 3 May 2021
- Vol. 183 (18)
[Viral pneumonia in immunocompetent adults].
In this review, we discuss viral pneumonias in an overall setting. Viruses are involved in about a quarter of all pneumonias, but despite literature in the past couple of decades emphasising this, the clinical effect remains elusive, and almost all hospitalised patients with pneumonia are treated with antibiotics. Thus, improved diagnostic methods and further research on the subject have the potential to benefit the overall treatment of patients with pneumonia, decrease antibiotic overconsumption and accelerate development of new antiviral therapeutics.
- 3 May 2021
- Vol. 183 (18)
[Viral pneumonia in immunocompetent adults].
In this review, we discuss viral pneumonias in an overall setting. Viruses are involved in about a quarter of all pneumonias, but despite literature in the past couple of decades emphasising this, the clinical effect remains elusive, and almost all hospitalised patients with pneumonia are treated with antibiotics. Thus, improved diagnostic methods and further research on the subject have the potential to benefit the overall treatment of patients with pneumonia, decrease antibiotic overconsumption and accelerate development of new antiviral therapeutics.